Catheter Precision (VTAK)
XASE:VTAK
Want to see VTAK full AI Analyst Report?
Top Page
Catheter Precision
(NYSE MKT:VTAK)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.73
▼(-59.83% Downside)
Action:Reiterated
Date:05/18/26
The score is driven primarily by very weak financial performance (tiny revenue base, severe losses, and sustained cash burn), which elevates ongoing financing risk. Technicals add further pressure with a clear downtrend across key moving averages and negative MACD, even though momentum is oversold. Valuation provides limited support because negative earnings make P/E less informative and there is no dividend yield.
Positive Factors
Proprietary electrophysiology mapping catheter
Catheter Precision’s core offering is a specialized electrophysiology mapping catheter used in ablation procedures. A focused, proprietary device targeting a clinical procedure creates a durable product moat, procedure‑based recurring demand, and a clear commercial value proposition to electrophysiology labs over months to years.
Negative Factors
Extremely negative operating margins
Margins are deeply negative and persist across reporting periods, reflecting a cost base far above current revenue. Such extreme operating losses undermine internal profitability prospects, necessitate ongoing external funding, and make sustainable margin recovery a critical structural hurdle for long‑term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary electrophysiology mapping catheter
Catheter Precision’s core offering is a specialized electrophysiology mapping catheter used in ablation procedures. A focused, proprietary device targeting a clinical procedure creates a durable product moat, procedure‑based recurring demand, and a clear commercial value proposition to electrophysiology labs over months to years.
Read all positive factors
Catheter Precision (VTAK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.28M
Dividend YieldN/A
Average Volume (3M)309.34K
Price to Earnings (P/E)―
Beta (1Y)1.35
Revenue Growth130.35%
EPS Growth92.24%
CountryUS
Employees22
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-6.79
Shares Outstanding2,692,473
10 Day Avg. Volume759,143
30 Day Avg. Volume309,336
Financial Highlights & Ratios
PEG Ratio-0.83
Price to Book (P/B)280.34
Price to Sales (P/S)2414.57
P/FCF Ratio-237.88
Enterprise Value/Market Cap5.46
Enterprise Value/Revenue14.50
Enterprise Value/Gross Profit12.30
Enterprise Value/Ebitda-0.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-60.8
Revenue Forecast (FY)$10.20M
Catheter Precision Business Overview & Revenue Model
Company Description
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's ...
How the Company Makes Money
Catheter Precision makes money primarily by selling its electrophysiology mapping catheters and related disposables used in hospital catheterization/electrophysiology labs during arrhythmia procedures. Revenue is generated on a per-procedure basis...
Catheter Precision Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
35
Negative
Cash Flow
10
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 819.00K | 420.00K | 442.00K | 14.00K | 22.00K |
| Gross Profit | 756.00K | 378.00K | 412.00K | -147.00K | -1.54M |
| EBITDA | -17.11M | -11.30M | -15.11M | -22.37M | -25.85M |
| Net Income | -17.18M | -16.64M | -70.57M | -26.86M | -25.07M |
Balance Sheet | |||||
| Total Assets | 15.86M | 27.77M | 30.74M | 16.84M | 21.04M |
| Cash, Cash Equivalents and Short-Term Investments | 88.00K | 2.87M | 3.56M | 15.86M | 15.04M |
| Total Debt | 3.85M | 1.79M | 372.00K | 0.00 | 2.26M |
| Total Liabilities | 9.21M | 16.01M | 9.54M | 7.58M | 7.37M |
| Stockholders Equity | 7.05M | 11.76M | 21.19M | 9.26M | 13.67M |
Cash Flow | |||||
| Free Cash Flow | -8.31M | -9.34M | -20.70M | -22.59M | -27.89M |
| Operating Cash Flow | -8.30M | -9.27M | -20.62M | -22.57M | -27.63M |
| Investing Cash Flow | 167.00K | -67.00K | -61.00K | 21.00K | 3.80M |
| Financing Cash Flow | 5.34M | 8.65M | 8.39M | 23.36M | 14.96M |
Catheter Precision Technical Analysis
Negative
1.81
Price Trends
1.00
Negative
1.41
Negative
1.94
Negative
Market Momentum
-0.06
Negative
45.20
Neutral
31.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTAK, the sentiment is Negative. The current price of 1.81 is above the 20-day moving average (MA) of 0.87, above the 50-day MA of 1.00, and below the 200-day MA of 1.94, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 45.20 is Neutral, neither overbought nor oversold. The STOCH value of 31.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VTAK.
Catheter Precision Risk Analysis
Catheter Precision disclosed 40 risk factors in its most recent earnings report. Catheter Precision reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Issued shares of our convertible preferred stock are convertible into a substantial number of shares of common stock that, upon conversion, will significantly dilute our existing common stockholders. Q1, 2026
2.
We may issue additional series of convertible preferred stock under the Series C Purchase Agreements that, upon issuance and conversion, could result in extraordinary additional dilution to our existing common stockholders. Q1, 2026
3.
The market for short-range flights is still in relatively early stages of development, and the UAM, RAM and AAM markets may not develop as anticipated. Q1, 2026
Catheter Precision Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $3.45M | -0.28 | -191.39% | ― | ― | 64.06% | |
45 Neutral | $45.75M | ― | -9999.00% | ― | -95.74% | -118.94% | |
44 Neutral | $2.81M | -0.13 | -6046.59% | ― | -0.20% | 91.63% | |
41 Neutral | $2.28M | -181.99 | -173.74% | ― | 130.35% | 92.24% | |
39 Underperform | $6.31M | -1.29 | -220.42% | ― | ― | 51.71% |
* Healthcare Sector Average
VTAK
Catheter Precision
0.85
-2.72
-76.25%
NUWE
Nuwellis
1.05
-36.35
-97.19%
AEMD
Aethlon Medical
2.20
-28.16
-92.75%
PAVM
PAVmed
6.39
-13.31
-67.56%
HSCS
Heart Test Laboratories, Inc.
1.98
-2.30
-53.74%
Catheter Precision Corporate Events
M&A TransactionsPrivate Placements and Financing
Catheter Precision Raises Capital Through New Preferred Stock
Positive
Apr 23, 2026
On April 21, 2026, Catheter Precision closed the sale of 3,470 shares of its newly created Series C-2 Convertible Preferred Stock at $1,000 per share, raising gross proceeds of $3.47 million to be used for working capital and general corporate nee...
Business Operations and StrategyShareholder MeetingsStock Split
Catheter Precision Shareholders Approve Reverse Split, Capital Changes
Neutral
Apr 15, 2026
On April 15, 2026, Catheter Precision held a Special Meeting of stockholders where approximately 49.5% of outstanding common shares were represented. Shareholders approved the issuance of common shares underlying the company’s Series C-1, C-...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Catheter Precision Announces Strategic Financing and Aviation Acquisition
Neutral
Mar 9, 2026
On March 9, 2026, Catheter Precision entered into a private placement with accredited investors to issue multiple new series of convertible preferred stock, initially raising $1.85 million and potentially up to roughly $39 million through addition...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.